Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma.

Leukemia·2024
Same author

Synthesis of Trifluoromethylated Monoterpenes by an Engineered Cytochrome P450.

Chemistry (Weinheim an der Bergstrasse, Germany)·2023
Same author

Primary breast diffuse large B-cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group.

Cancer medicine·2023
Same author

Therapeutic drug monitoring of perospirone: The lowest effective plasma concentration in patients with schizophrenia.

Asian journal of psychiatry·2023
Same author

Insight of the State for Deliberately Introduced A-Site Defect in Nanofibrous LaFeO<sub>3</sub> for Boosting Artificial Photosynthesis of CH<sub>3</sub>OH.

ACS applied materials & interfaces·2023
Same author

Nitrous oxide emissions in novel wastewater treatment processes: A comprehensive review.

Bioresource technology·2023

Related Experiment Video

Updated: Sep 9, 2025

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment &#8212; Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.5K

ZBED4: A Prognostic Biomarker and Therapeutic Target in Hepatocellular Carcinoma.

Jing Ding1, Xia Zou1, Xuefeng Huang1,2

  • 1Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, Sichuan, People's Republic of China.

Journal of Hepatocellular Carcinoma
|August 28, 2025
PubMed
Summary
This summary is machine-generated.

ZBED4, a protein, is linked to poor prognosis in hepatocellular carcinoma (HCC) and influences immune cell infiltration. It may serve as a biomarker for predicting treatment response in HCC patients.

Keywords:
ZBED4hepatocellular carcinomaimmune infiltrationpan-cancerprognosistherapy

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.0K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.4K

Related Experiment Videos

Last Updated: Sep 9, 2025

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment &#8212; Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.5K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.0K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.4K

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death, with limited treatment options.
  • Investigating novel therapeutic targets and strategies is crucial for improving HCC outcomes.
  • The specific role of ZBED4 in cancer development and progression is not well understood.

Purpose of the Study:

  • To investigate the role of ZBED4 in hepatocellular carcinoma (HCC).
  • To evaluate ZBED4 as a potential prognostic and therapeutic biomarker in HCC.
  • To explore the relationship between ZBED4 expression and the tumor immune microenvironment in HCC.

Main Methods:

  • Data mining from TCGA, GEO, ICGC, and GDSC databases.
  • Bioinformatic analyses using R software and web platforms.
  • Validation using multiplex immunofluorescence on HCC tissue microarrays.

Main Results:

  • High ZBED4 expression correlates with poor prognosis and altered immune cell infiltration across multiple cancers.
  • In HCC, ZBED4 levels inversely correlate with CD8+ T cells but positively correlate with Tregs and neutrophils.
  • Elevated ZBED4 is associated with reduced response to immunotherapy but improved response to chemotherapy and targeted therapy in HCC patients.

Conclusions:

  • ZBED4 plays a significant role in regulating the tumor immune microenvironment in HCC.
  • ZBED4 serves as a potential prognostic biomarker for HCC.
  • ZBED4 expression may predict patient response to different therapeutic strategies, including immunotherapy and chemotherapy.